199 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information 30.
Other non-current liabilities 2017 2016 m m Accruals and deferred income 104 66 Consumer Healthcare put option liability 7,420 Other payables 877 959 981 8,445 31.
Net debt 2017 2016 Listing exchange m m Current assets: Liquid investments 78 89 Cash and cash equivalents 3,833 4,897 3,911 4,986 Short-term borrowings: Commercial paper 529 1,094 Bank loans and overdrafts 236 332 Obligations under finance leases 23 23 1.50% US$ US Medium Term Note 2017 New York Stock Exchange 1,612 5.625% European Medium Term Note 2017 London Stock Exchange 1,068 5.65% US$ US Medium Term Note 2018 New York Stock Exchange 2,037 2,825 4,129 Long-term borrowings: 5.65% US$ US Medium Term Note 2018 New York Stock Exchange 2,216 0.625% European Medium Term Note 2019 London Stock Exchange 1,324 1,276 0% European Medium Term Note 2020 London Stock Exchange 1,060 2.85% US$ US Medium Term Note 2022 New York Stock Exchange 1,474 1,603 2.8% US$ US Medium Term Note 2023 New York Stock Exchange 919 999 1.375% European Medium Term Note 2024 London Stock Exchange 876 845 4.00% European Medium Term Note 2025 London Stock Exchange 659 635 1% European Medium Term Note 2026 London Stock Exchange 617 3.375% European Medium Term Note 2027 London Stock Exchange 593 593 1.375% European Medium Term Note 2029 London Stock Exchange 439 5.25% European Medium Term Note 2033 London Stock Exchange 986 986 5.375% US$ US Medium Term Note 2034 London Stock Exchange 368 401 6.375% US$ US Medium Term Note 2038 New York Stock Exchange 2,021 2,199 6.375% European Medium Term Note 2039 London Stock Exchange 695 695 5.25% European Medium Term Note 2042 London Stock Exchange 989 988 4.2% US$ US Medium Term Note 2043 New York Stock Exchange 363 395 4.25% European Medium Term Note 2045 London Stock Exchange 789 789 Obligations under finance leases 43 41 Other long term borrowings 49 14,264 14,661 Net debt 13,178 13,804
